GLP1R and type 2 diabetes mellitus: The meta-analyses of clinical trials in which the GLP-1 RA liraglutide was used in psoriatic patients with T2DM demonstrated positive effects on PASI score and fasting plasma glucose level, but also showed that liraglutide treatment in these patients had no effects on DLQI, BMI, or HbA1c [23].